Structural analysis of silanediols as transition-state-analogue inhibitors of the benchmark metalloprotease thermolysin

被引:47
作者
Juers, DH [1 ]
Kim, J
Matthews, BW
Sieburth, SM
机构
[1] Univ Oregon, Inst Mol Biol, Howard Hughes Med Inst, Eugene, OR 97403 USA
[2] Univ Oregon, Dept Phys, Eugene, OR 97403 USA
[3] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA
[4] Temple Univ, Dept Chem, Philadelphia, PA 19122 USA
关键词
D O I
10.1021/bi051346v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dialkylsilanediols have been found to be an effective functional group for the design of active-site-directed protease inhibitors, including aspartic (HIV protease) and metallo (ACE and thermolysin) proteases. The use of silanediols is predicated on its resemblance to the hydrated carbonyl transition-state structure of amide hydrolysis. This concept has been tested by replacing the presumed tetrahedral carbon of a thermolysin substrate with a silanediol group, resulting in an inhibitor with an inhibition constant K-i = 40 nM. The structure of the silanediol bound to the active site of thermolysin was found to have a conformation very similar to that of a corresponding phosphonamidate inhibitor (Ki = 10 nM). In both cases, a single oxygen is within bonding distance to the active-site zinc ion, mimicking the presumed tetrahedral transition state. There are binding differences that appear to be related to the presence or absence of protons on the oxygens attached to the silicon or phosphorus. This is the first crystal structure of an organosilane bound to the active site of a protease.
引用
收藏
页码:16524 / 16528
页数:5
相关论文
共 47 条
[1]   Insights in the peptide hydrolysis mechanism by thermolysin:: A theoretical QM/MM study [J].
Antonczak, S ;
Monard, G ;
López, MR ;
Rivail, JL .
JOURNAL OF MOLECULAR MODELING, 2000, 6 (7-8) :527-538
[2]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[3]  
Barrett A. G. M., 1991, COMPREHENSIVE ORGANI, P235
[4]   Recent advances in matrix metalloproteinase inhibitor research [J].
Beckett, RP ;
Davidson, AH ;
Drummond, AH ;
Huxley, P ;
Whittaker, M .
DRUG DISCOVERY TODAY, 1996, 1 (01) :16-26
[5]   Matrix metalloprotease inhibitors: design from structure [J].
Borkakoti, N .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :17-20
[6]   ASSESSMENT OF PHASE ACCURACY BY CROSS VALIDATION - THE FREE R-VALUE - METHODS AND APPLICATIONS [J].
BRUNGER, AT .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1993, 49 :24-36
[7]   Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease [J].
Chen, CA ;
Sieburth, SM ;
Glekas, A ;
Hewitt, GW ;
Trainor, GL ;
Erickson-Viitanen, S ;
Garber, SS ;
Cordova, B ;
Jeffry, S ;
Klabe, RM .
CHEMISTRY & BIOLOGY, 2001, 8 (12) :1161-1166
[8]   SILICONE GREASE AS A PRECURSOR TO A PSEUDOCROWN ETHER LIGAND - CRYSTAL-STRUCTURE OF [K+]3[K(ME2SIO)7+][INH(CH2CME3)3-]4 [J].
CHURCHILL, MR ;
LAKE, CH ;
CHAO, SHL ;
BEACHLEY, OT .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1993, (20) :1577-1578
[9]   Metalloproteinases: their role in arthritis and potential as therapeutic targets [J].
Clark, IM ;
Parker, AE .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (01) :19-34
[10]   Phosphinic acid compounds in biochemistry, biology and medicine [J].
Collinsová, M ;
Jirácek, J .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (06) :629-647